An Important Milestone: Bioperfectus EUROGIN 2022 Review

Company news
2022-04-13

After two years of expectation, the world’s most significant international in-person conference on HPV-related diseases, EUROGIN, was successfully held in Congress Center, Düsseldorf, from April 10-12, 2022.  

 

At EUROGIN 2022, Bioperfectus HPV Testing Total Solution attracted many esteemed scholars and laboratory technicians’ attention; Some of our end-users and partners traveled from Austria, Poland, Serbia, and other countries to visit our booth EUROGIN and spoke highly of Bioperfectus Nucleic Acid Extraction Solution.

 

The unique design of the Bioperfectus extraction instrument SMPE960 with three independent modules and the PCR instrument STC-96A PLUS with two separate modules and covering 21 HPV genotyping became the spotlight of the conversation between our customers and partners at EUROGIN 2022.

 

As the bronze sponsor of EUROGIN 2022, we, Bioperfectus, would like to take this opportunity to thank the organizer of EUROGIN and our European partners for their strong support and to all the audience and guests who came to visit us from afar. We look forward to meeting you face-to-face at EUROGIN in the coming year.

 

 

After two years of expectation, the world’s most significant international in-person conference on HPV-related diseases, EUROGIN, was successfully held in Congress Center, Düsseldorf, from April 10-12, 2022.  

MOST READ

Bioperfectus Supports Cholera Elimination

SHANGHAI, CHINA, December 5, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance.

2022-11-30

Client Story: A Race Against Time

Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.

2022-11-15

Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).

2022-11-14